262 related articles for article (PubMed ID: 22321046)
21. [Malignant mesothelioma and constitutional BAP1 gene mutations].
Neviere Z; Berthet P; Polycarpe F; Dubos-Arvis C; Dô P; Gervais R
Rev Mal Respir; 2019 Feb; 36(2):241-248. PubMed ID: 30686559
[TBL] [Abstract][Full Text] [Related]
22. An asbestos-exposed family with multiple cases of pleural malignant mesothelioma without inheritance of a predisposing BAP1 mutation.
Cheung M; Kadariya Y; Pei J; Talarchek J; Facciolo F; Visca P; Righi L; Cozzi I; Testa JR; Ascoli V
Cancer Genet; 2015 Oct; 208(10):502-7. PubMed ID: 26364129
[TBL] [Abstract][Full Text] [Related]
23. Molecular and immunohistochemical characterisation of mesothelioma of the tunica vaginalis
Anderson WJ; Sholl LM; Fletcher CDM; Schulte S; Wang LJ; Maclean FM; Hirsch MS
Histopathology; 2022 Jul; 81(1):65-76. PubMed ID: 35460532
[TBL] [Abstract][Full Text] [Related]
24. Malignant mesothelioma in situ: diagnostic and clinical considerations.
Pulford E; Henderson DW; Klebe S
Pathology; 2020 Oct; 52(6):635-642. PubMed ID: 32829890
[TBL] [Abstract][Full Text] [Related]
25. Mesothelioma families without inheritance of a BAP1 predisposing mutation.
Ascoli V; Cozzi I; Vatrano S; Izzo S; Giorcelli J; Romeo E; Carnovale-Scalzo C; Grillo LR; Facciolo F; Visca P; Papotti M; Righi L
Cancer Genet; 2016 Sep; 209(9):381-387. PubMed ID: 27751355
[TBL] [Abstract][Full Text] [Related]
26. Whole exome sequencing reveals BAP1 somatic abnormalities in mesothelioma in situ.
Dacic S; Roy S; Lyons MA; von der Thusen JH; Galateau-Salle F; Churg A
Lung Cancer; 2020 Nov; 149():1-4. PubMed ID: 32932212
[TBL] [Abstract][Full Text] [Related]
27. Testing for BAP1 loss and CDKN2A/p16 homozygous deletion improves the accurate diagnosis of mesothelial proliferations in effusion cytology.
Chevrier M; Monaco SE; Jerome JA; Galateau-Salle F; Churg A; Dacic S
Cancer Cytopathol; 2020 Dec; 128(12):939-947. PubMed ID: 32678499
[TBL] [Abstract][Full Text] [Related]
28. High Incidence of Somatic BAP1 alterations in sporadic malignant mesothelioma.
Nasu M; Emi M; Pastorino S; Tanji M; Powers A; Luk H; Baumann F; Zhang YA; Gazdar A; Kanodia S; Tiirikainen M; Flores E; Gaudino G; Becich MJ; Pass HI; Yang H; Carbone M
J Thorac Oncol; 2015 Apr; 10(4):565-76. PubMed ID: 25658628
[TBL] [Abstract][Full Text] [Related]
29. Prevalence of BRCA-1 associated protein 1 germline mutation in sporadic malignant pleural mesothelioma cases.
Rusch A; Ziltener G; Nackaerts K; Weder W; Stahel RA; Felley-Bosco E
Lung Cancer; 2015 Jan; 87(1):77-9. PubMed ID: 25468148
[TBL] [Abstract][Full Text] [Related]
30. Molecular characterization of diffuse malignant peritoneal mesothelioma.
Hung YP; Dong F; Torre M; Crum CP; Bueno R; Chirieac LR
Mod Pathol; 2020 Nov; 33(11):2269-2279. PubMed ID: 32504035
[TBL] [Abstract][Full Text] [Related]
31. Genomic Deletion of
Sarun KH; Lee K; Williams M; Wright CM; Clarke CJ; Cheng NC; Takahashi K; Cheng YY
Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30301262
[TBL] [Abstract][Full Text] [Related]
32. Utility of BAP1 Immunohistochemistry and p16 (CDKN2A) FISH in the Diagnosis of Malignant Mesothelioma in Effusion Cytology Specimens.
Hwang HC; Sheffield BS; Rodriguez S; Thompson K; Tse CH; Gown AM; Churg A
Am J Surg Pathol; 2016 Jan; 40(1):120-6. PubMed ID: 26448191
[TBL] [Abstract][Full Text] [Related]
33. BAP1 gene mutations in Egyptian patients with advanced sporadic malignant pleural mesothelioma (MPM): relation with clinical outcomes and survival.
Bahnasy AA; El-Din RS; Sabri NA; Abdel-Rahman CA; Bastawisy AE
Cancer Genet; 2018 Dec; 228-229():83-92. PubMed ID: 30553477
[TBL] [Abstract][Full Text] [Related]
34. Utility of Methylthioadenosine Phosphorylase Compared With BAP1 Immunohistochemistry, and CDKN2A and NF2 Fluorescence In Situ Hybridization in Separating Reactive Mesothelial Proliferations From Epithelioid Malignant Mesotheliomas.
Berg KB; Dacic S; Miller C; Cheung S; Churg A
Arch Pathol Lab Med; 2018 Dec; 142(12):1549-1553. PubMed ID: 30059257
[TBL] [Abstract][Full Text] [Related]
35. Germline BAP1 Mutational Landscape of Asbestos-Exposed Malignant Mesothelioma Patients with Family History of Cancer.
Ohar JA; Cheung M; Talarchek J; Howard SE; Howard TD; Hesdorffer M; Peng H; Rauscher FJ; Testa JR
Cancer Res; 2016 Jan; 76(2):206-15. PubMed ID: 26719535
[TBL] [Abstract][Full Text] [Related]
36. BAP1 facilitates diagnostic objectivity, classification, and prognostication in malignant pleural mesothelioma.
McGregor SM; Dunning R; Hyjek E; Vigneswaran W; Husain AN; Krausz T
Hum Pathol; 2015 Nov; 46(11):1670-8. PubMed ID: 26376834
[TBL] [Abstract][Full Text] [Related]
37. Further evidence for germline BAP1 mutations predisposing to melanoma and malignant mesothelioma.
Cheung M; Talarchek J; Schindeler K; Saraiva E; Penney LS; Ludman M; Testa JR
Cancer Genet; 2013 May; 206(5):206-10. PubMed ID: 23849051
[TBL] [Abstract][Full Text] [Related]
38. Frequent deletion of 3p21.1 region carrying semaphorin 3G and aberrant expression of the genes participating in semaphorin signaling in the epithelioid type of malignant mesothelioma cells.
Yoshikawa Y; Sato A; Tsujimura T; Morinaga T; Fukuoka K; Yamada S; Murakami A; Kondo N; Matsumoto S; Okumura Y; Tanaka F; Hasegawa S; Hashimoto-Tamaoki T; Nakano T
Int J Oncol; 2011 Dec; 39(6):1365-74. PubMed ID: 21842119
[TBL] [Abstract][Full Text] [Related]
39. New Markers for Separating Benign From Malignant Mesothelial Proliferations: Are We There Yet?
Churg A; Sheffield BS; Galateau-Salle F
Arch Pathol Lab Med; 2016 Apr; 140(4):318-21. PubMed ID: 26288396
[TBL] [Abstract][Full Text] [Related]
40. Biallelic germline and somatic mutations in malignant mesothelioma: multiple mutations in transcription regulators including mSWI/SNF genes.
Yoshikawa Y; Sato A; Tsujimura T; Otsuki T; Fukuoka K; Hasegawa S; Nakano T; Hashimoto-Tamaoki T
Int J Cancer; 2015 Feb; 136(3):560-71. PubMed ID: 24916674
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]